MedTrace Logo

REstore Working Ability in RheumatoiD Arthritis

NCT01405326 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2011-07-29

No results posted yet for this study

Summary

The purpose of the study is to assess whether a 6-month treatment with adalimumab added on the treatment with conventional antirheumatic drugs (DMARD) will decrease the number of days on sick leave compared to placebo. In addition, the cost-effectiveness and cost-utility of the intervention compared to the conventional treatment is evaluated, and the patients who benefit most are characterized.

Conditions

Interventions

BIOLOGICAL

adalimumab

40mg sc. every two weeks for six months

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • The Rheumatological Center of Helsinki

    lead NETWORK

Principal Investigators

  • Kari K Eklund, MD · The Rheumatological Center of Helsinki

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-12-31
Completion
2013-03-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01405326 on ClinicalTrials.gov